Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma

BACKGROUND: Increasing bodies of evidence reveal that targeting a programmed cell death protein 1 (PD-1) monoclonal antibody is a promising immunotherapy for lung adenocarcinoma. Although PD receptor ligand 1 (PDL1) expression is widely recognized as the most powerful predictive biomarker for anti-P...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiaoguang, Qi, Chunyan, Kang, Xindan, Hu, Yi, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315620/
https://www.ncbi.nlm.nih.gov/pubmed/32607285
http://dx.doi.org/10.7717/peerj.9362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315620/
https://www.ncbi.nlm.nih.gov/pubmed/32607285
http://dx.doi.org/10.7717/peerj.9362

Ejemplares similares